Induction of novel regulatory T cells by JAK inhibitor and its application for inflammatory disease treatment
| Project/Area Number |
23791105
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
OKAMOTO Akiko 東京大学, 保健・健康推進本部, 助教 (40431861)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | JAK 阻害薬 / 制御性T細胞 / 全身性エリテマトーデス(systemic lupus erythematosus; SLE)コラーゲン誘導性関節炎 / JAK阻害薬 / 自己免疫疾患 / 全身性エリテマトーデス / ＪＡＫ阻害薬 / 関節炎 |
|---|
| Research Abstract |
We have recently identified a novel regulatory T cells (Treg) population that expresses lymphocyte activation gene-3(LAG3) and early growth response gene-2(Egr2). LAG3+ Treg strongly suppress autoantibody production. Young DBA1J mice and lupus-prone NZB/W F1 mice had fewer LAG3+ Treg in the spleen compared with control B6mice. We found that in vivo tofacitinib, a JAK inhibitor, treatment increased ofCD4+CD25-LAG3+ regulatory cells in the spleen of B6 mice. We found that tofacitinib, a JAK inhibitor, induces LAG3+ Treg-like CD4+Egr2+ T cells (Tofa T cells) in vitro. Tofa T cells suppressed autoantibody production and nephritis progression in BWF1 mice. LAG3+ Treg and Tofa-T cells significantly suppressed the progression of collagen induced arthritis (CIA)in DBA1J mice. Tofacitinib conferred the expression of regulatory molecules and in vivo suppressive function on CD4+ T cells. The induction of LAG3+ Treg would contribute the regulation of chronic inflammatory diseases.
|
Report
(3 results)
Research Products
(21 results)
